152 results
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
* Phase 1b/2a (CENDIFOX) Tumor immuno-profiling pre- & post- treatment and LSTA1 effectiveness assessment in combination with chemo and an EGFR inhibitor … Biopsy Screening EUS & Biopsy At weeks 12-16 Tumor burden assessment at screening, cycle 2, and then 8-weekly thereafter. Patients are treated with 28
8-K
EX-99.2
LSTA
Lisata Therapeutics Inc
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
) Tumor immuno-profiling pre- & post- treatment and LSTA1 effectiveness assessment in combination with chemo and an EGFR inhibitor (open label) Qilu … completion Biopsy Screening Biopsy Week 12 Tumor burden assessment at screening, cycle 2, and then 8-weekly thereafter. Patients are treated with 28-day cycles
8-K
EX-99.2
8d2oyh 6v11o58ivy8cq
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
skh3 cn4nqqrz4
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
ndhful3cx91j ia
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
8-K/A
EX-99.1
hnl93rd4qn31zl
4 Oct 22
Other Events
4:42pm
8-K
EX-99.2
jbabh qo1y7qavffaj4
5 Aug 22
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:01pm
424B3
rr5vva0bbilnju
29 Jul 22
Prospectus supplement
4:06pm